Eptifibatide
Also known as: Integrilin
Key Facts: Eptifibatide
- Category
- Hormonal
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - Acute coronary syndrome and PCI
- Administration
- IV bolus and infusion
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Duration
- Up to 72 hours
Mechanism of Action
Platelets stick together by linking their glycoprotein IIb/IIIa receptors to fibrinogen, the final common step that builds a blood clot. Eptifibatide is a competitive antagonist that plugs the IIb/IIIa receptor using a KGD (Lys-Gly-Asp) recognition sequence, so fibrinogen cannot bridge one platelet to the next and aggregation grinds to a halt. The molecule binds reversibly and clears quickly, with a plasma half-life of roughly 2.5 hours, so platelet function recovers within hours of stopping the infusion. That fast on, fast off behavior is exactly what you want in a hospital setting where bleeding risk has to be controlled.
Research Summary
Eptifibatide is backed by large randomized human trials, not preliminary data. The PURSUIT trial published in the New England Journal of Medicine in 1998 enrolled over 10,000 patients with acute coronary syndromes without ST elevation and found eptifibatide reduced the combined rate of death or nonfatal myocardial infarction compared with placebo. The ESPRIT trial showed that a two-bolus plus infusion regimen during stenting cut the 30-day rate of death, MI, or urgent revascularization from about 10.4 percent to 6.8 percent versus placebo. Across these trials the main trade-off is bleeding, and unlike some older agents eptifibatide was not found to be immunogenic or to commonly cause thrombocytopenia. Its pharmacology is well characterized, with a short half-life that makes the antiplatelet effect rapidly reversible. In short, this is a mature, evidence-based drug whose benefits and risks in cardiac care are clearly established.
Dosing Information
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
Hospital/procedural use
Doses from Studies
180 mcg/kg IV bolus
2 mcg/kg/min infusion up to 72 hours
Duration
Up to 72 hours
Administration
IV bolus and infusion
Timing & Administration
Best Time to Take
Morning or as directed
Follow recommended protocol
Food Recommendation
With or without food
Why This Timing?
Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Bleeding (28% - most common)
- ●Major bleeding (3-10%)
- ●Hypotension
- ●Thrombocytopenia
- ●Allergic reactions
- ●High-risk medication per ISMP
- ●FDA approved (Integrilin)
References
- https://pubmed.ncbi.nlm.nih.gov/9705684/
- https://www.ncbi.nlm.nih.gov/books/NBK541066/
- https://pubmed.ncbi.nlm.nih.gov/12846593/
- https://pubmed.ncbi.nlm.nih.gov/9291241/
Research This Peptide Further
Frequently Asked Questions
What does Eptifibatide do?
Eptifibatide is an FDA-approved intravenous antiplatelet drug, sold as Integrilin, and it has an oddly cool origin: it is a synthetic cyclic heptapeptide modeled on barbourin, a protein from the venom of the southeastern pygmy rattlesnake. It is used in hospitals during acute coronary syndromes and percutaneous coronary intervention (PCI, the stent procedure) to stop platelets from clumping and forming dangerous clots. This is a real, approved cardiac drug, not a wellness or research peptide.
How does Eptifibatide work?
Platelets stick together by linking their glycoprotein IIb/IIIa receptors to fibrinogen, the final common step that builds a blood clot. Eptifibatide is a competitive antagonist that plugs the IIb/IIIa receptor using a KGD (Lys-Gly-Asp) recognition sequence, so fibrinogen cannot bridge one platelet to the next and aggregation grinds to a halt. The molecule binds reversibly and clears quickly, with a plasma half-life of roughly 2.5 hours, so platelet function recovers within hours of stopping the infusion. That fast on, fast off behavior is exactly what you want in a hospital setting where bleeding risk has to be controlled.
Is Eptifibatide FDA approved?
Yes, Eptifibatide is FDA approved. FDA Approved - Acute coronary syndrome and PCI
What are the side effects of Eptifibatide?
Reported side effects include: Bleeding (28% - most common), Major bleeding (3-10%), Hypotension, Thrombocytopenia, Allergic reactions. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Eptifibatide?
Community-reported common dose: Limited community data available (See research protocols). Range: See research dosing. Administration: IV bolus and infusion. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Eptifibatide or used in similar applications.
Oxytocin
FDAOxytocin is a 9-amino-acid hormone made in the hypothalamus, famous as the chemistry behind labor contractions, breastfeeding, and social bonding. As an injectable drug it is FDA-approved to induce labor and control postpartum bleeding, but the intranasal 'love hormone' versions sold for trust, anxiety, and autism are experimental and the human results are genuinely mixed. The hype runs well ahead of the evidence.
HormonalGonadorelin
FDAGonadorelin is a synthetic copy of natural GnRH (gonadotropin-releasing hormone), a 10-amino-acid peptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that tells the pituitary to release LH and FSH. It is FDA-approved for evaluating pituitary function and has historical use in inducing ovulation. In the peptide world it is mostly used off-label to keep the testes working during testosterone replacement, and the catch is that timing matters enormously: pulse it and you stimulate, give it continuously and you shut the system down.
HormonalLeuprolide
FDALeuprolide (brand name Lupron) is a synthetic GnRH agonist, a modified peptide about 20 times more potent than natural GnRH, and it is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The clever part is counterintuitive: it works by overstimulating the GnRH system so hard that the pituitary shuts down sex hormone production. It is a real, long-established prescription drug, not a research peptide, and it carries meaningful side effects from the low-hormone state it creates.
HormonalDesmopressin
FDADesmopressin (dDAVP) is a synthetic tweak of the natural hormone vasopressin, redesigned to keep the water-retaining effect while dropping most of the blood-pressure effect. It is a long-established FDA-approved drug used for central diabetes insipidus, bedwetting and nocturia, and certain bleeding disorders like von Willebrand disease and mild hemophilia A. This is settled medicine, not an experimental peptide, and its main real-world danger is straightforward: it can drop your blood sodium dangerously low if you drink too much fluid on it.
HormonalOctreotide
FDAOctreotide is a synthetic eight-amino-acid mimic of the natural hormone somatostatin, the body's main 'off switch' for hormone secretion. It shuts down excess growth hormone, so it is a frontline FDA-approved drug for acromegaly, and it also tames the flushing and diarrhea of hormone-secreting carcinoid and other neuroendocrine tumors. This is real, approved medicine with decades of clinical data behind it, sold as Sandostatin (injectable, since 1988), Sandostatin LAR (monthly depot), and Mycapssa (oral capsule, approved 2020).
HormonalLanreotide
FDALanreotide is an eight-amino-acid somatostatin analog, a close cousin of octreotide, given as a long-acting deep-injection gel (Somatuline Depot/Autogel) usually once a month. It is FDA-approved for acromegaly and for gastroenteropancreatic neuroendocrine tumors, and it carries an approval for carcinoid syndrome. It is established prescription medicine, not an experimental compound.
HormonalWant updates on Eptifibatide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.